Biomarker Core

生物标志物核心

• 批准号: 10263709
• 负责人: Lynn Bekris
• 金额: $ 35.34万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10263709
• 关键词: Address; African American; Alleles; Alzheimer' s Disease; Alzheimer' s disease related dementia; Amyloid beta-42; Biological Assay; Biological Markers; Blood; CCL2 gene; CXCL10 gene; Cataloging; Catalogs; Cerebrospinal Fluid; Clinic; Clinical Data; Collaborations; Collection; Communities; Consultations; DNA; Data; Data Set; Data Storage and Retrieval; Databases; Dementia; Dementia with Lewy Bodies; Diagnosis; Discrimination; Disease; Disease Progression; Ensure; Foundations; Future; Genetic; Genetic Diseases; Genetic Markers; Genotype; Goals; Heterogeneity; Human; Human Resources; Inflammation; Infrastructure; International; Light; Link; Medical Genetics; Medical center; Mentors; Mission; Molecular; Molecular Analysis; Molecular Genetics; Monitor; National Institute on Aging; Neurochip; Neurodegenerative Disorders; Other Genetics; Participant; Pathogenicity; Pathology; Plasma; Population; Population Heterogeneity; Process; Protein Analysis; Research; Research Personnel; Research Project Grants; Saliva; Sampling; Secure; Skin; Specimen; Symptoms; System; TREM2 gene; Therapeutic; Time; Training; Translations; Underrepresented Populations; United States Department of Veterans Affairs; Universities; University Hospitals; Urine; alpha synuclein; apolipoprotein E-4; base; biobank; biological heterogeneity; biomarker discovery; chemokine; clinically relevant; cytokine; data exchange; data management; distributed data; education research; genetic analysis; genetic variant; imaging biomarker; improved; innovation; neurofilament; neuropathology; presenilin-1; programs; protein aggregation; protein biomarkers; repository; specific biomarkers; success; tau Proteins; tau-1

PROJECT SUMMARY The mission of the Biomarker Core (BC) is to support Alzheimer's disease (AD) and AD-related dementias (AD/ADRD) research projects by collecting, storing, tracking, sharing, and analyzing biospecimens and associated clinical, genetic, and biomarker data. The collected clinical, genetic, and biomarker data on a variety of human biospecimens will contribute to the understanding of AD/ADRD underlying heterogeneity by cataloging the onset, progression, and disease symptoms of participant biospecimens currently stored in the Cleveland Alzheimer's Disease Research Center (CADRC) BC. This information will contribute to improving diagnosis in unique, understudied populations, as well as the population as a whole. Toward this mission, we previously established and integrated biospecimen collection and research collaborations between Case Western Reserve University, Cleveland Clinic, MetroHealth Systems, University Hospitals, and the Louis Stoke Cleveland VA Medical Center. The aims of the BC are to 1) Facilitate research by leveraging and expanding the CADRC BC infrastructure and biospecimens linked with participant clinical data in the integrated database and continue to include longitudinal biospecimen collection, 2) Provide basic biomarker characterization to facilitate AD/ADRD research, 3) Provide basic genetic characterization to facilitate AD/ADRD research, and 4) Distribute biospecimens to neurodegenerative disease consortiums and coordinating centers, as well as to internal and external investigators. Toward these aims, our team of experts will continue to contribute to biospecimen collection for the CADRC. The establishment of the CADRC BC has provided an essential infrastructure to facilitate and integrate the independent projects of unique and understudied populations, such as African Americans, as well as understudied neurodegenerative disorders, including atypical AD and dementia with Lewy bodies. Standard clinical data (the Uniform Data Set) from these diverse understudied populations will continue to be linked with generated biomarker and genetic data. Genetic and biomarker data linked to relevant clinical data in accordance with goals of the National Alzheimer's Project Act (NAPA) are shared with the scientific community including the Alzheimer's Disease Genetic Consortium (ADGC), National Alzheimer's Coordinating Center (NACC), and the National Institute on Aging Genetics of Alzheimer's Disease Data Storage (NIAGADS). The already established CCLRCBH-Biobank and our highly trained personnel has insured seamless creation of the CADRC BC. Importantly, the CADRC BC infrastructure is now in place to facilitate future innovative AD/ADRD research projects that enhances our understanding of the heterogeneity of AD/ADRD pathology.

项目摘要 生物标志物核心（BC）的使命是支持阿尔茨海默病（AD）和AD相关痴呆症 (AD/ADRD）研究项目，通过收集、储存、跟踪、共享和分析生物标本， 相关的临床、遗传和生物标志物数据。收集的临床、遗传和生物标志物数据， 各种人体生物标本将有助于理解AD/ADRD潜在的异质性， 对目前储存在 克利夫兰阿尔茨海默病研究中心（CADRC）BC。这些信息将有助于改善 诊断在独特的，未充分研究的人群，以及作为一个整体的人口。为了这个使命，我们 以前建立和整合的生物标本收集和研究合作之间的情况下， 西储大学、克利夫兰诊所、MetroHealth Systems、大学医院和路易斯斯托克 克利夫兰退伍军人医疗中心BC的目标是：1）通过利用和扩大 CADRC BC基础设施和与集成数据库中的参与者临床数据相关联的生物标本 并继续包括纵向生物标本采集，2）提供基本的生物标志物表征， 促进AD/ADRD研究，3）提供基本的遗传特征，以促进AD/ADRD研究，以及4） 将生物样本分发给神经退行性疾病联盟和协调中心，以及 内部和外部调查员。为了实现这些目标，我们的专家团队将继续为以下方面做出贡献： 为CADRC收集生物标本建立CADRC BC提供了一个重要的 基础设施，以促进和整合独特的和未充分研究的人口，如独立的项目 作为非裔美国人，以及研究不足的神经退行性疾病，包括非典型AD和 路易体痴呆标准临床数据（统一数据集）来自这些不同的研究 人口将继续与生成的生物标志物和遗传数据相关联。基因和生物标志物数据 根据国家阿尔茨海默病项目法案（NAPA）的目标， 与科学界分享，包括阿尔茨海默病遗传联盟（ADGC），国家 阿尔茨海默氏症协调中心（NACC）和国家阿尔茨海默氏症衰老遗传学研究所 数据存储（NIAGADS）。已经建立的CCLRCBH-Biobank和我们训练有素的人员已经 确保CADRC BC的无缝创建。重要的是，CADRC BC基础设施现已到位， 促进未来创新的AD/ADRD研究项目，提高我们对异质性的理解 AD/ADRD病理学。